VHCP Management II LLC increased its position in shares of Ascendis Pharma A/S (NASDAQ:ASND) by 31.7% in the third quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 1,299,052 shares of the biotechnology company’s stock after purchasing an additional 312,560 shares during the quarter. Ascendis Pharma A/S makes up approximately 13.0% of VHCP Management II LLC’s holdings, making the stock its 3rd biggest holding. VHCP Management II LLC owned approximately 3.57% of Ascendis Pharma A/S worth $47,091,000 at the end of the most recent reporting period.

Other institutional investors have also recently made changes to their positions in the company. Bank of Montreal Can increased its position in shares of Ascendis Pharma A/S by 127.4% during the 2nd quarter. Bank of Montreal Can now owns 4,535 shares of the biotechnology company’s stock worth $126,000 after purchasing an additional 2,541 shares in the last quarter. Bank of America Corp DE increased its position in shares of Ascendis Pharma A/S by 23.6% during the 1st quarter. Bank of America Corp DE now owns 5,345 shares of the biotechnology company’s stock worth $150,000 after purchasing an additional 1,020 shares in the last quarter. Victory Capital Management Inc. acquired a new stake in shares of Ascendis Pharma A/S during the 3rd quarter worth about $194,000. Aperio Group LLC acquired a new stake in shares of Ascendis Pharma A/S during the 3rd quarter worth about $241,000. Finally, Deschutes Portfolio Strategy LLC acquired a new stake in shares of Ascendis Pharma A/S during the 2nd quarter worth about $238,000. Institutional investors and hedge funds own 78.93% of the company’s stock.

Shares of Ascendis Pharma A/S (NASDAQ:ASND) opened at $36.61 on Tuesday. Ascendis Pharma A/S has a 1 year low of $19.21 and a 1 year high of $42.00.

ASND has been the subject of several research reports. Wedbush restated an “outperform” rating and issued a $10.71 price objective (down previously from $65.00) on shares of Ascendis Pharma A/S in a research report on Friday, September 22nd. Bank of America restated a “buy” rating and issued a $36.00 price objective (up previously from $34.00) on shares of Ascendis Pharma A/S in a research report on Monday, September 25th. Credit Suisse Group restated an “outperform” rating and issued a $50.00 price objective (up previously from $30.00) on shares of Ascendis Pharma A/S in a research report on Friday, September 22nd. Wells Fargo & Company restated a “buy” rating and issued a $51.00 price objective on shares of Ascendis Pharma A/S in a research report on Friday, September 22nd. Finally, Zacks Investment Research cut shares of Ascendis Pharma A/S from a “hold” rating to a “sell” rating in a research report on Wednesday, August 23rd. Two equities research analysts have rated the stock with a sell rating, two have assigned a hold rating and five have assigned a buy rating to the company. The stock has a consensus rating of “Hold” and a consensus target price of $36.45.

COPYRIGHT VIOLATION WARNING: This article was originally reported by TheOlympiaReport and is the sole property of of TheOlympiaReport. If you are accessing this article on another website, it was illegally copied and reposted in violation of United States and international trademark and copyright law. The legal version of this article can be read at https://theolympiareport.com/2017/12/05/vhcp-management-ii-llc-purchases-312560-shares-of-ascendis-pharma-as-asnd.html.

Ascendis Pharma A/S Company Profile

Ascendis Pharma A/S is a clinical-stage biopharmaceutical company. The Company is engaged in applying its TransCon technology to develop sustained release prodrug therapies with several product candidates in clinical and preclinical development. The Company is developing its product candidate, TransCon human growth hormone (TransCon hGH) for once-weekly administration to treat growth hormone deficiency (GHD) and other indications.

Institutional Ownership by Quarter for Ascendis Pharma A/S (NASDAQ:ASND)

Receive News & Ratings for Ascendis Pharma A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ascendis Pharma A/S and related companies with Analyst Ratings Network's FREE daily email newsletter.